VSTM ▲ +20.3% - Verastem, Inc.
$VSTM VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease
14-OCT-2026 06:01 AM ET
Share this post
More filings for $VSTM
VSTM ▲ +0.1% - Verastem, Inc.Oct 2, 2026VSTM ▼ -1.0% - Verastem, Inc.Sep 24, 2026VSTM ▲ +0.6% - Verastem, Inc.Sep 8, 2026VSTM - Verastem, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026VSTM - Verastem, Inc. - SEC Filing Update (07-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 7, 2026$VSTM SEC Filing Update (31-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 31, 2026
View full $VSTM filing history →💬 Comments
Loading comments…
Leave a comment